



HAL
open science

Increased risk of IRIS-associated tuberculosis in HIV-infected patients receiving Integrase Inhibitors

A. Gaillet, R. Calin, P. Flandre, R. Tubiana, M.-A. Valantin, E. Caumes, C. Katlama, V. Pourcher

► To cite this version:

A. Gaillet, R. Calin, P. Flandre, R. Tubiana, M.-A. Valantin, et al.. Increased risk of IRIS-associated tuberculosis in HIV-infected patients receiving Integrase Inhibitors. *Infectious Diseases Now*, 2021, 51 (1), pp.90-93. 10.1016/j.medmal.2020.09.005 . hal-03280354

HAL Id: hal-03280354

<https://hal.sorbonne-universite.fr/hal-03280354>

Submitted on 7 Jul 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Médecine et Maladies Infectieuses

"Titre" Augmentation du risque de syndrome de restauration immunitaire chez les patients co-infectés VIH-tuberculose sous inhibiteurs d'intégrase.

"Titre secondaire" Increased risk of IRIS-associated tuberculosis in HIV infected patients receiving Integrase Inhibitors

--Manuscript Draft--

Manuscript Number:	
Article Type:	Short Communication
Section/Category:	General Infectiology
Keywords:	HIV, IRIS-associated tuberculosis-associated IRIS, integrase inhibitors, INSTI
Corresponding Author:	Antoine Gaillet Assistance Publique - Hopitaux de Paris Paris, FRANCE
First Author:	Antoine Gaillet
Order of Authors:	Antoine Gaillet Ruxandra Calin, Ph Philippe Flandre Roland Tubiana, Ph Marc-antoine Valantin, Ph Eric Caumes, MD PhD Christine Katlama, MD PhD Valérie Pourcher, MD PhD
Abstract:	<p>Contexte: Le traitement par inhibiteurs d'intégrase (INSTI) est recommandé en première intention chez infectés par le VIH-1 naïfs. La tuberculose est associée à un sur-risque de syndrome de restauration immunitaire (SRI) induit par les anti-rétroviraux. Il existe peu de données quant au sur-risque spécifique des INSTI dans cette situation.</p> <p>Méthode: Tous les patients co-infectés par le VIH et la tuberculose, et suivis dans le service de maladie infectieuse de la Pitié Salpêtrière entre 1997 et 2017 ont été évalués. Ceux présentant les critères de SRI (paradoxe et maladie) dans les 6 mois suivant l'introduction du traitement anti-rétroviral ont été inclus. Nous avons évalué l'incidence de SRI associé à la tuberculose selon le régime anti-rétroviral.</p> <p>Résultats: Cinquante-cinq patients ont été inclus: 21 recevaient un régime anti-rétroviral comportant des INSTI et 34 un régime sans INSTI. À l'exception du régime antirétroviral, les deux groupes étaient comparables (taux initial médian CD4 = 85 / mm³). Le pourcentage global de SRI était de 34% (19/55), avec 52% de SRI sous INSTI et 23% sans INSTI (p = 0,04). En régression logistique multivariée, nous avons observé un sur-risque de SRI sous INSTI avec un OR à 3,33 [IC 95%, 1,01-11,1] (p = 0,05). Il n'y avait pas de différence de sévérité des SRI entre les deux groupes.</p> <p>Conclusions: Les inhibiteurs d'intégrase pourraient être associés à un sur-risque de SRI associé à la tuberculose. Des études prospectives sont nécessaires pour déterminer quel est le schéma thérapeutique optimal chez les patients co-infectés TB-VIH.</p>

ART containing integrase inhibitors could be associated with a higher incidence of TB-associated IRIS. Prospective studies are needed to better characterized the risk of IRIS-TB and determine which is the optimal ART regimen in TB-HIV coinfectd patients.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Background:

1
2 Tuberculosis is associated with a risk of immune reconstitution inflammatory syndrome
3
4 (IRIS) after ART initiation.
5

Methods:

6
7
8
9 Data from all patients with newly diagnosed tuberculosis disease and uncontrolled HIV
10
11 infection from 1997 to 2017 in a French center were retrospectively collected. We evaluated
12
13 the incidence of tuberculosis-IRIS in patients initiating ART with or without integrase
14
15 inhibitors (INSTI).
16
17

Results:

18
19
20
21 Fifty-five patients were included: 21 receiving an INSTI regimen and 34 a non-INSTI
22
23 regimen. Except ART regimen, the two groups were comparable (median CD4 of 85/mm³).
24
25 The overall percentage of IRIS was 34% (19/55), with respectively 52% IRIS in INSTI
26
27 regimen and 23% in non INSTI regimen (p=0.04). In a multivariate logistic model, we
28
29 observed an increased risk of IRIS in the INSTI regimen compared to the non-INSTI with an
30
31 OR at 3.33 [95% CI, 1.01-11.1] (p=0.05).
32
33
34
35

Conclusions:

36
37
38
39 ART containing integrase inhibitors could be associated with a higher incidence of TB-IRIS.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

SHORT COMMUNICATION

**Increased risk of IRIS-associated tuberculosis in HIV infected patients receiving
Integrase Inhibitors**

Antoine GAILLET¹, Ruxandra CALIN^{1, 2}, Philippe FLANDRE², Roland TUBIANA^{1, 2},
Marc-Antoine VALANTIN^{1, 2}, Eric CAUMES^{1, 2}, Christine KATLAMA^{1, 2}, Valérie
POURCHER^{1,2}

¹ Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Department of Infectious
Diseases, Pitie-Salpetriere Hospital, Paris

² INSERM UMR-S 1136, Pierre Louis Institute of Epidemiology and Public Health, Sorbonne
Université, Paris

Conflicts of Interest and Sources of Funding:

All authors declare no conflicts of interest.

Corresponding Author:

Dr Antoine Gaillet

Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Department of Infectious
Diseases, Pitie-Salpetriere Hospital, Paris

47-83 Boulevard de l'Hôpital

Paris, 75013, France

Phone: + 33 1 42 16 02 62

Fax: + 33 1 42 16 01 24

gaillet.antoine75@gmail.com

Introduction

1
2 HIV-associated tuberculosis (TB) is common with an estimation of 900.000 cases including
3
4 300.000 deaths annually.¹ Antiretroviral therapy (ART) is essential to reduce morbidity-
5
6 mortality of HIV-infected patients. However, ART initiation can lead to tuberculosis-
7
8 associated immune reconstitution inflammatory syndrome (TB-IRIS) with a prevalence of 4
9
10 to 54%.² TB-IRIS is an immunopathological reaction characterized by recurrent and
11
12 inflammatory complications of TB in a patient already on TB treatment after starting ART
13
14 (paradoxical TB-IRIS), or a new diagnosis of TB after starting ART (unmasking TB-IRIS).^{3, 4}
15
16 TB-IRIS is a serious reaction leading to hospitalization in 25% of cases, and IRIS-attributable
17
18 death in about 2%.^{2, 4} The major risk factors associated with the development of TB-IRIS are
19
20 a shorter duration between TB treatment initiation and ART initiation, disseminated-TB,
21
22 lower CD4 cell counts, higher viral load (VL) at ART introduction, the degree and kinetics of
23
24 VL decrease and CD4 cell count increase after the start of ART.^{2, 5}
25
26 Treatment with integrase strand transfer inhibitors (INSTI) is recommended as first regimen
27
28 by treatment-guidelines for ART naive HIV-1 infected.⁶⁻⁸ Pre-marketing phase III studies
29
30 assessing INSTI efficiency included very few late-presenters (patients with $CD4 < 200/mm^3$ or
31
32 opportunistic infections (OI))^{7, 8}, patients at the highest risk for developing TB-IRIS. As few
33
34 data about INSTI-associated TB-IRIS are available, we report a cohort of TB-HIV co-infected
35
36 patients, comparing IRIS characteristics according to the ART regimen.
37
38
39
40
41
42
43
44
45
46
47

Methods

Database:

48
49
50
51 We retrospectively collected data from patients followed for HIV and TB between 1997 and
52
53 2017 in the computerized and anonymous medical file of the Department of Infectious
54
55 Diseases of Pitié Salpêtrière hospital in Paris (Nadis).⁹
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Study population:

All patients with concomitant *Mycobacterium tuberculosis* infection and uncontrolled HIV infection (naive or without current treatment) were included. We excluded HIV-2 and atypical mycobacteria infections in order to ensure overall homogeneity. The data used fulfilled the confidentiality criteria of the “Commission Nationale de l'Informatique et des Libertés” (CNIL 2085894), and were extracted from medical informatics charts named NADIS, with signed patient consent, authorizing exploitation of data.

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
Diagnostic criteria:

TB diagnosis was established on bacteriological samples or according to a set of arguments: clinical and radiological presentations, differential diagnosis exclusion and improvement under specific treatment.

Criteria for TB-IRIS diagnosis were based on the consensus definitions from The International Network for the Study of HIV-associated IRIS (INSHI) of paradoxical and unmasking TB-IRIS^{3,4}. IRIS not related to TB was excluded.

The diagnosis of IRIS, according to INSHI criteria, was made by two independent observers unblinded.

34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
Follow-up:

We recorded the clinical, biological (VL, CD4 cell count), and radiological data up to 6 months after ART initiation, issued from systematic follow-up consultations (2 or 3 visits within 6 months) and hospitalizations in severe cases.

51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
Analysis:

Between-group characteristics were analyzed using either exact Fisher test (binary variables) or Kruskal-Wallis test (continuous variables). A multivariate logistic model (including age at TB, higher VL, lower CD4 count, ART timing of introduction, ART regimen) was used to

1 determine risk factors for IRIS. Quantitative variables were expressed as median, minimal,
2 maximal while qualitative variables were expressed as a percentage.
3
4
5

6 7 **Results**

8
9 Of all TB infected patients followed in our Center from 1997 to 2017, 82 were eligible and
10 screened, and we enrolled 55 HIV-1 TB patients who met the inclusion criteria (Figure 1): 21
11 in INSTI group 1 and 34 in non-INSTI group 2. Apart from ART regimen, the
12 epidemiological, clinical, and biological characteristics of the two groups were not different.
13
14 (Table 1) Only one cerebral-tuberculosis received pre-emptive corticosteroids.
15
16

17 At baseline, median viral load and CD4 cell count were 5.44 Log₁₀ copies/ml [2.3-6.74] and
18 89/mm³ [2-391] respectively. HIV infection was previously known in 43% and 29% of
19 patients respectively in INSTI and non-INSTI groups (treatment discontinuation in 9/9 in
20 INSTI, 11/13 in non-INSTI group).
21

22 ART treatment was introduced within a median of 2 weeks (-3 to 8 weeks) after anti-
23 tuberculosis treatment (mainly consists of a quadritherapy based on rifampin/rifabutin,
24 isoniazid, ethambutol, pyrazinamide) and this lag-time was not significantly different between
25 groups (p = 0.18).
26
27

28 The overall percentage of IRIS was 34% (19/55), with respectively 52% IRIS in INSTI
29 regimen and 23% in non-INSTI regimen, which was significantly different (p=0.04). In both
30 groups, median time for IRIS occurrence after ART initiation was about 3 weeks, with a
31 median viral load decrease of 2.51 log₁₀ copies/ml (INSTI = 2.7 log₁₀ copies/ml ; non-INSTI
32 = 2.0 log₁₀ copies/ml) and a median increase in CD4 count of 47/mm³ (INSTI = 63/mm³ ;
33 non-INSTI = 31/mm³). There were too few data to statistically prove the faster downward
34 trend in VL and the faster rise of CD4 driven by INSTI.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 In a multivariate logistic model, we observed an increased risk of IRIS in the INSTI regimen
2 compared to the non-INSTI with an OR at 3.33 [95% CI, 1.01-11.1] (p = 0.05). However,
3
4 there was no significant difference in terms of hospitalization rate, and IRIS-related
5
6 corticosteroid use (respectively 4 hospitalizations and 5 corticosteroid introductions in each
7
8 group). The only death occurred in a patient with cerebral tuberculosis treated, two weeks
9
10 after anti-tuberculosis and corticosteroids, with INSTI. This patient had an initial CD4 count
11
12 of 104/mm³.
13
14
15

16 Few secondary OI have been reported in each group: one toxoplasmosis and two CMV
17
18 plasma replications in group 1, and 4 CMV plasma replications in group 2.
19
20
21
22
23
24
25

26 **Discussion**

27
28 ART containing integrase inhibitors seemed to be associated with a higher incidence of TB-
29
30 IRIS compared to non-INSTI regimen. Overall incidence of IRIS (34%) in our patients is
31
32 within the rates found in similar series with HIV-TB co-infected late-presenters.²
33
34

35 Since INSTI are more promptly efficient on VL than other class of ART, it seems logical that
36
37 a treatment based on INSTI could increase the rate of IRIS, especially in a population at high
38
39 risk of IRIS. However the data reported so far are weak and contradictory.¹⁰⁻¹⁶
40
41
42

43 Several observational studies have reported an association between ART containing integrase
44
45 inhibitors and all-cause of IRIS.¹⁰⁻¹² A retrospective monocentric study including 417 HIV
46
47 infected patients treated with ART, with 92 OI (only 8 cases of tuberculosis) at diagnosis,
48
49 identified 45 cases of IRIS, and found, in multivariate analysis, INSTI use (OR 2.89; 95% CI
50
51 1.26-6.64; p=0.012) as an independent risk factor of IRIS.¹⁰ The ATHENA cohort in the
52
53 Netherlands, including 369 HIV treatment-naïve patients with CD4 ≤ 200/mm³ and
54
55 concomitant OI (of which 51 mycobacterial infections unspecified about the type), found in a
56
57 regression model that INSTI use was independently associated with any form of IRIS (HR
58
59
60
61
62
63
64
65

1 2.6, 95% CI 1.3-5.1, p=0.004), and *Mycobacterium avium* complex-related IRIS (HR 2.46,
2 95% CI 1.04-5.84, p=0.041). However, there was no precise information about TB-IRIS,
3 probably related to the low number of cases.¹¹ Lastly, in a large prospective multicentric
4 cohort including 2,287 HIV infected patients (398 in INSTI group, compared to non-INSTI
5 treatment) with an average rate of pre-ART CD4+ T cell count of 83/mm³, IRIS requiring
6 hospitalization occurred in 41 patients, respectively in 3% (12/398) and 1.5% (29/1889,
7 p=0.05). Generalized linear modelisation showed that all-cause IRIS was associated with
8 INSTI use (OR 1.96 (1.07-3.43)). TB-IRIS was recorded in 12 cases, without difference
9 between groups (5 cases under INSTI) keeping in mind the small number of cases.¹²

10
11
12
13
14
15
16
17
18
19
20
21 At the opposite, in an open-label trial including 153 HIV/TB co-infected patients randomized
22 in 3 groups of either raltegravir (400 mg or 800 mg/day) or efavirenz, there were few (5%)
23 and equally distributed IRIS between the 3 groups (respectively 2, 4 and 3). Nevertheless, the
24 mean initial CD4 count was > 100/mm³ (140/mm³) and the delay between TB treatment and
25 ART initiation was 5.7 weeks, potentially explaining the lower risk of IRIS.¹³ Moreover, a
26 recent meta-analysis addressing dolutegravir use did not find an association with IRIS but all
27 the analyzed randomized trials excluded late-presenters.¹⁴ Finally, the REALITY trial
28 randomized 1,805 naïve patients with CD4<100/mm³ to standard ART (2NRTI+NNRTI) +
29 raltegravir (n=902) vs standard ART alone (n=903) and enhanced prophylaxis versus standard
30 prophylaxis. This study did not find any difference in the incidence of all-cause IRIS (TB,
31 cryptococcosis, Kaposi, viral hepatitis, CMV and unknown pathogen) between the 2 groups,
32 including for TB-IRIS (which occurred in 53 (5.9%) vs 54 (6.0%) respectively (p=1.00)).
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
This study did not differentiate new TB diagnosis during follow-up from unmasking IRIS
(196 cases). In addition, endpoints were predominantly clinically defined, as microbiological
and other diagnostic facilities were limited in most centers, the validity of the IRIS diagnosis
seems therefore relative in regards to the international validated criteria^{15, 16}

1 Our study has several limitations mostly related to the observational, retrospective, open and
2 monocentric characteristics. In addition, the small number of patients limits the multivariate
3 analysis. However, our results are issued from the comparison of two groups of patients that
4 prove homogenous and similar in terms of relevant characteristics and bring new data
5 concerning the possible role of INSTI containing regimens in TB-IRIS development in HIV
6 late presenters or uncontrolled patients. Prospective studies are needed to better characterize
7 the risk factors for TB-IRIS in this patient population, to determine which might be the
8 optimal care (ART regimen, pre-emptive corticosteroid therapy) to reduce occurrence of IRIS
9 and avoid drug-drugs interactions.
10
11
12
13
14
15
16
17
18
19
20
21
22
23

24 **References**

- 25
26 [1]. World Health Organization. Global Tuberculosis Report, 2018
27 (https://www.who.int/tb/publications/global_report/en/)
28
29
30
31 [2] Namale PE, Abdullahi LH, Fine S, Kamkuemah M, Wilkinson RJ, Meintjes G.
32 Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis. *Future*
33 *Microbiol* 2015; 10:1077–1099.
34
35
36
37
38 [3] Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W et al.
39 Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for
40 use in resourcelimited settings. *Lancet Infect Dis* 2008; 8:516–523.
41
42
43
44
45 [4] Manabe YC, Breen R, Perti T, Girardi E, Sterling TR. Unmasked tuberculosis and
46 tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation
47 of antiretroviral therapy. *J Infect Dis* 2009; 199:437–444.
48
49
50
51 [5] Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M; IeDEA Southern and
52 Central Africa. Immune reconstitution inflammatory syndrome in patients starting
53
54
55
56
57
58
59
60
61
62
63
64
65

antiretroviral therapy for HIV infection: a systematic review and meta-analysis. *Lancet Infect Dis* 2010; 10: 251-61.

[6] Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adult: 2018 Recommendations of the International Antiviral Society-USA Panel. *JAMA* 2018; 24; 320(4):379-396.

[7] Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. *N Engl J Med*. 2013 Nov 7; 369(19):1807-18.

[8] Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48 weeks results from the randomised open-label phase 3b study. *Lancet*. 2014 Jun 28; 383(9936):2222-31.

[9] Dossier médical informatisé pour les patients atteints d'infection par le VIH (ADDIS) : l'expérience du Service des Maladies Infectieuses du CHU de Nice. Pradier C, Pugliese P, Caissotti C, S Wehrlen-Martini, Huynh-Van E, Pueyo B, Dellamonica P. *Méd Mal Inf*. 1998 ;28 :291-5.

[10] Psychogiou M, Basoulis D, Tsikala-Vafea M, Vlachos S, Kapelios CJ, Daikos GL. Integrase strand transfer inhibitors and the emergence of immune reconstitution inflammatory syndrome (IRIS). *Curr HIV Res* 2017; 15:405–410.

[11] Wijting I, Rokx C, Wit F, Postma A, Hoepelman A, Van der Ende M et al. Integrase inhibitors are an independent risk factor for IRIS; an ATHENA-Cohort study. In: Conference on Retroviruses and Opportunistic Infections (CROI 2017), Seattle, 2017 [abstract 731].

1 [12] Dutertre M, Cuzin L, Demonchy E, Puglièse P, Joly V, Valantin MA et al. Initiation of
2 Antiretroviral Therapy Containing Integrase Inhibitors Increases the Risk of IRIS Requiring
3 Hospitalization. *J Acquir Immune Defic Syndr*. 2017 Sep 1;76(1):e23-e26.
4
5

6 [13] Grinsztejn B, De Castro N, Arnold V, Veloso VG, Morgado M, Pilotto JH et al.
7 Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180
8 Replate TB): a multicentre, phase 2, noncomparative, open-label, randomised trial. *Lancet*
9 *Infect Dis* 2014; 14:459–467.
10
11


12 [14] Hill AM, Mitchell N, Hughes S, Pozniak AL. Risks of cardiovascular or central nervous
13 system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir
14 versus other antiretrovirals: meta-analysis of randomized trials. *Curr Opin HIV AIDS* 2018;
15 13:102–111.
16

17 [15] Hakim J, Musiime V, Szubert AJ Mallewa J, Siika A, Agutu C et al, Enhanced
18 Prophylaxis plus Antiretroviral Therapy for Advanced HIV in Africa. *N Engl J Med*. 2017 Jul
19 20; 377(3):233-245.
20
21

22 [16] Kityo C, Szubert AJ, Siika A, Heyderman R, Bwakura-Dangarembizi M, Lugemwa A et
23 al. Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A
24 randomised controlled trial. *PLoS Med*. 2018 Dec 4; 15(12):e1002706.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1: Flow chart

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65



[Click here to access/download](#)
Table
MMI_IRIS_Table1.pdf

Conceptualization: Antoine GAILLET ; Ruxandra CALIN ; Valérie POURCHER

Data curation: Antoine GAILLET

Formal analysis: Philippe FLANDRE

Project administration: Valérie POURCHER ;

Supervision: Ruxandra CALIN ; Valérie POURCHER

Roles/Writing - original draft: Antoine GAILLET

Writing - review & editing: Ruxandra CALIN ; Roland TUBIANA ; Marc-Antoine VALANTIN ; Eric CAUMES ; Christine KATLAMA ; Valérie POURCHER

The data used fulfilled the confidentiality criteria of the “Commission Nationale de l'Informatique et des Libertés” (CNIL 2085894), and were extracted from medical informatics charts named NADIS, with signed patient consent, authorizing exploitation of data.